Company intelligence / Profile preview

Sirius NeoSight

Tassin-la-Demi-Lune, Auvergne Rhône Alpes, Francesirius-neosight.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has completed proof of concept on human cancer cells in vitro, in mouse tumors in vivo, and on patient samples in a large-scale exploratory study. Currently conducting transversal clinical studies in collaboration with Hospices Civils de Lyon (HCL) and the Léon Bérard Centre (CLB)[7].

Therapeutic areas: Oncology
Modalities: Diagnostic technology for cancer detection and therapeutic prediction
Industry: Molecular Diagnostics

Drug pipeline

1 asset

OSTA27

Pre-clinical

Indications: Metastatic cancer

Partnerships

Centre Léon Bérard in LyonInstitut de Cancérologie de l'Ouest (ICO)Hospices Civils de Lyon (HCL)CNRSUniversity of Lyon[2][7]

Beyond the preview

Go deeper on Sirius NeoSight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sirius NeoSight.

Explore the full profile